Patents by Inventor Mario R. W. Ehlers

Mario R. W. Ehlers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual ACE C-domain/NEP inhibitors
    Patent number: 11129805
    Abstract: A superior dual ACE/NEP inhibitor is a combination that selectively targets the ACE C-domain in addition to inhibiting NEP. Such a dual ACE C-domain/NEP inhibitor can be used in the treatment of diverse cardiovascular diseases, including hypertension and heart failure.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 28, 2021
    Assignee: ANGIODESIGN (UK) LIMITED
    Inventors: Edward D. Sturrock, Mario R. W. Ehlers
  • DUAL ACE C-DOMAIN/NEP INHIBITORS
    Publication number: 20190111014
    Abstract: A superior dual ACE/NEP inhibitor is a combination that selectively targets the ACE C-domain in addition to inhibiting NEP. Such a dual ACE C-domain/NEP inhibitor can be used in the treatment of diverse cardiovascular diseases, including hypertension and heart failure.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 18, 2019
    Inventors: Edward D. STURROCK, Mario R.W. EHLERS
  • Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
    Patent number: 6982248
    Abstract: Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: January 3, 2006
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Thomas R. Coolidge, Mario R. W. Ehlers
  • Use of three-dimensional crystal structure coordinates to design and synthesize domain-selective inhibitors for angiotensin-converting enzyme (ACE)
    Publication number: 20040033532
    Abstract: It has now been discovered that the use of the three-dimensional crystal structure coordinates of angiotensin-converting enzyme (ACE) will enable the design and synthesis, by means of computational chemistry and structure-guided drug design, of inhibitors of ACE that are highly selective and specific for either the N domain or the C domain of the enzyme, for the treatment of diverse diseases. The invention also relates to methods and processes for the structure-guided design and synthesis of dual N- and C-domain ACE inhibitors, and inhibitors that operate by competitive, non-competitive, uncompetitive, and irreversible mechanisms.
    Type: Application
    Filed: August 8, 2003
    Publication date: February 19, 2004
    Inventors: Mario R. W. Ehlers, Barton Holmquist
  • Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused skeletal muscle tissue
    Publication number: 20020147131
    Abstract: Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.
    Type: Application
    Filed: September 11, 2001
    Publication date: October 10, 2002
    Inventors: Thomas R. Coolidge, Mario R.W. Ehlers
  • Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
    Patent number: 6429197
    Abstract: It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: August 6, 2002
    Assignee: Bionebraska, Inc.
    Inventors: Thomas R. Coolidge, Mario R. W. Ehlers
  • Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
    Publication number: 20020055460
    Abstract: Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.
    Type: Application
    Filed: May 9, 2001
    Publication date: May 9, 2002
    Inventors: Thomas R. Coolidge, Mario R.W. Ehlers
  • Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
    Patent number: 6284725
    Abstract: Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: September 4, 2001
    Assignee: BioNebraska, Inc.
    Inventors: Thomas R. Coolidge, Mario R. W. Ehlers
  • Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
    Patent number: RE41288
    Abstract: It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: April 27, 2010
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Thomas R. Coolidge, Mario R. W. Ehlers